Intel stock spikes after report of possible US government stake
NASHVILLE - Cryoport, Inc. (NASDAQ:CYRX), currently valued at $346 million in market capitalization, has completed the divestiture of its specialty courier business, CRYOPDP, to DHL Group for approximately $200 million in cash, the temperature-controlled supply chain solutions provider announced Thursday. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.56x.
Alongside the sale, the companies have established a strategic partnership focused on enhancing supply chain service offerings for the global life sciences and healthcare sector. The collaboration aims to combine Cryoport’s specialized supply chain expertise with DHL’s global health logistics infrastructure. InvestingPro analysis shows the company operates with a moderate debt level, with a debt-to-equity ratio of 0.67.
"With this partnership, we are enhancing our core capabilities as we develop a strong global partner network," said Jerrell Shelton, CEO of Cryoport. "We believe this partnership with DHL will enhance our positioning in the Asia Pacific and Europe, Middle East and Africa regions."
The transaction provides Cryoport with additional capital as the company focuses on advancing its Life Science Services platform globally, particularly in the regenerative medicine market, according to the company’s statement.
Cryoport specializes in temperature-controlled supply chain solutions for the life sciences industry, offering services including advanced temperature-controlled packaging, logistics management, and cryogenic systems.
The company maintains its headquarters in Nashville, Tennessee, with additional locations across the Americas, EMEA, and APAC regions.
Additional details about the transaction will be available in Cryoport’s current report on Form 8-K to be filed with the Securities and Exchange Commission, according to the press release statement.
In other recent news, Cryoport Inc. reported its first-quarter 2025 earnings, revealing an earnings per share (EPS) of -$0.28, which exceeded the forecasted -$0.31. However, the company did not meet revenue expectations, generating $41 million against a forecast of $58.96 million. Despite the revenue miss, Cryoport experienced a 10% year-over-year revenue increase, with life sciences services revenue up by 17% and commercial cell and gene therapies growing by 33%. The company also confirmed its full-year 2025 revenue guidance of $165-$172 million, representing a 7.5% growth at the midpoint. In strategic moves, Cryoport announced a partnership with DHL and the sale of Cryo PDP for $195 million, aiming to enhance its global logistics capabilities. The company anticipates continued growth in commercial cell and gene therapies, with expectations for low to mid-single-digit product revenue growth. Furthermore, Cryoport’s strategic focus on supply chain diversification and a robust pipeline in cell and gene therapy development were emphasized during their earnings call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.